Description
Tradename:
Alzmenda
Compound:
Each tablet contains:
Memantine hydrochloride 10 mg 21 tab
Auxiliary components:
Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, macrogol, titanium dioxide.
Properties:
A drug for the treatment of dementia. It is a non-competitive antagonist of glutamate NMDA receptors (including in the substantia nigra), as a result of which it reduces the excessive stimulating effect of cortical glutamate neurons on the neostriatum, which develops against the background of insufficient release of dopamine. By reducing the flow of Ca2+ into neurons, it reduces the possibility of their destruction.
It has nootropic, cerebrovasodilating, antihypoxic and psychostimulating effects.
Improves weakened memory, increases the ability to concentrate, reduces fatigue and symptoms of depression, reduces spasticity of skeletal muscles caused by diseases or damage to the brain.
Indications:
Moderate to severe dementia due to Alzheimer’s disease
Directions for use and dosage:
The method of administration and dosage regimen of a particular drug depend on its release form and other factors. The optimal dosage regimen is determined by the doctor. The compliance of the dosage form of a particular drug with the indications for use and dosage regimen should be strictly observed.
When taken orally, the initial dose for adults is 10 mg/day. (1-7days).
In the future, the dose can be increased weekly by 10 mg. The average maintenance dose is 10-20 mg/day. The maximum dose is 20 mg/day.
Contraindications:
Hypersensitivity to memantine; severe liver failure; pregnancy; lactation period (breastfeeding); children and adolescents up to 18 years of age (the effectiveness and safety of the drug have not been established).
With caution: epilepsy, thyrotoxicosis, predisposition to the development of seizures, simultaneous use of NMDA receptor antagonists (amantadine, ketamine, dextromethorphan), factors that increase urine pH (sudden change of diet, for example, switching to vegetarianism, copious intake of alkaline gastric buffers), renal tubular acidosis, severe urinary tract infections caused by Proteus spp. , myocardial infarction (history), heart failure, uncontrolled arterial hypertension, renal failure, mild or moderate liver failure (class A and B according to the Child-Pugh classification).
Precautionary measures:
Use with caution in patients with epilepsy, renal failure, thyrotoxicosis, a history of seizures, arterial hypertension, a history of myocardial infarction, or heart failure.
Concomitant use of memantine and NMDA receptor antagonists such as amantadine, ketamine or dextromethorphan should be avoided. These compounds act on the same receptor system as memantine, therefore, adverse reactions (mainly related to the central nervous system) may occur more frequently and be more severe.
Side effects:
From the immune system: often – hypersensitivity reactions.
From the mental side: often – drowsiness; uncommon – confusion, hallucinations (mainly observed in patients with Alzheimer’s disease at the stage of severe dementia), frequency unknown – mental reactions.
From the nervous system: often – dizziness, imbalance; infrequently – gait disturbance; very rarely – convulsions.
From the cardiovascular system: often – increased blood pressure; uncommon – heart failure, venous thrombosis and/or thromboembolism. .
From the digestive system: often – constipation; infrequently – vomiting, nausea; frequency unknown – pancreatitis.
From the liver and biliary tract: often – increased levels of liver enzymes; frequency unknown – hepatitis.
From the hematopoietic system: frequency unknown – agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombocytopenic purpura.
Other: often – headache, shortness of breath; infrequently – fungal infections, fatigue; frequency unknown – acute renal failure, Stevens-Johnson syndrome.
Storage method:
At a temperature not higher than 30 degrees.
Package:
The cardboard box contains 2 blisters of 7 tablets, paper instructions.
